๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-05-20

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer (NCT04484909)

Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma

๐Ÿ”ต Active, Not Recruiting Phase1 ๐Ÿ“‹ Clinical Research Protocol Sponsor: M.D. Anderson Cancer Center

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

To find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.

Who can join: Review the eligibility criteria below.

Location: M D Anderson Cancer Center โ€” Houston, Texas

Age range: 18 Years

๐Ÿงช Interventions in This Study

  • Hafnium Oxide-containing Nanoparticles NBTXR3 (OTHER)
  • Radiation Therapy (RADIATION)

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • M D Anderson Cancer Center โ€” Houston, Texas

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—